The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Paion AG's Revenue for the
six
months ended in Jun. 2023 was $7.36 Mil. Paion AG's average Accounts Receivable for the
six
months ended in Jun. 2023 was $2.18 Mil.
Hence, Paion AG's Receivables Turnover for the
six
months ended in Jun. 2023 was 3.37.
Paion AG (OTCPK:PAIOF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Paion AG Receivables Turnover Related Terms
Paion AG Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Paion AG's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PAIOF vs ZTS, NBIX, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Paion AG's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paion AG Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Paion AG's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Paion AG's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paion AG (PAIOF) has a Receivables Turnover of 3.37 as of Jun. 2023. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Paion AG and its competitors.
Is Paion AG's Receivables Turnover too high?
Paion AG's current Receivables Turnover is 3.37. The Drug Manufacturers industry median Receivables Turnover is 5.07. Paion AG's value of 3.37 is 33.5% below this industry median. Overall, Paion AG has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Paion AG's Receivables Turnover compare to ZTS and NBIX?
Paion AG's Receivables Turnover of 3.37 can be compared against companies in the Drug Manufacturers industry. The industry median Receivables Turnover is 5.07. Paion AG's value of 3.37 is 33.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paion AG's current Receivables Turnover of 3.37 is 33.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Paion AG and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paion AG's current Receivables Turnover is 3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paion AG stock overvalued right now?
Paion AG (PAIOF) has a current Receivables Turnover of 3.37. The current Receivables Turnover is 3.37 and 33.5% below the Drug Manufacturers industry median of 5.07. Paion AG's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Paion AG (PAIOF), the current Receivables Turnover is 3.37 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Paion AG is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
10GF Score
Get the complete analysis for PAIOF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PAIOF has been successfully added to your 
